Latest Cancer immunotherapy Stories
BLUE BELL, Pa., March 15, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has signed an agreement with OncoSec Medical Inc. (OTC Bulletin Board: ONCS.D) providing for the sale to OncoSec of certain non-DNA vaccine technology and intellectual property relating to electroporation technology useful for electrochemical and cytokine based immune...
OXFORD, England, March 15, 2011 /PRNewswire-FirstCall/ -- - Immune Response Surrogate Algorithm Shownto be a Significant Predictor of Clinical Benefit Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces that further analyses of the TroVax(R) Renal Immunotherapy Survival Trial ("TRIST"), a randomised, double-blind, placebo-controlled Phase III study, have been accepted for publication in Cancer Immunology,...
CAMBRIDGE, Mass., Feb. 9, 2011 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by normalizing the immune response, presented results from preclinical studies with TRX518, a first-in-class immunomodulatory agent for the treatment of cancer. TRX518 is a monoclonal antibody reactive with the glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed to enhance the immune system's anti-tumor response...
BLUE BELL, Pa., Feb. 2, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of Inovio's SynCon(TM) DNA vaccine for prostate cancer targeting two antigens. While current prostate cancer therapies target single antigens, in this...
Scientists discovered a new way breast cancer cells dodge the immune system and promote tumor growth, providing a fresh treatment target in the fight against the disease. While comparable mechanisms to avoid the immune system have been identified in mice with breast and other cancers, the study tested human breast tumor cells, putting researchers closer to understanding how the disease progresses in real patients.The study, published in the journal Cancer Research, found high levels of the...
Researchers have found that a novel form of personalized therapy that genetically engineers a patient's own anti-tumor immune cells to fight tumors could treat metastatic melanoma and metastatic synovial cell sarcoma, representing a potentially new therapeutic approach against these and other cancers.The technique, called adoptive immunotherapy, works with the body's immune system to fight cancer. Immune cells, called T lymphocytes, are removed, modified, expanded in large numbers, and given...
WORCESTER, Mass., Jan. 25, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board:GNBT), together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc. (www.antigenexpress.com), announced today that it has amended the Clinical Study Agreement with The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (www.hjf.org) in regard to the on-going Phase II clinical study of Antigen's AE37 novel...
AMES, Iowa, Jan. 21, 2011 /PRNewswire/ -- NewLink Genetics Corporation today announced that additional data from its Phase 2 clinical trial of the company's investigational HyperAcute® Pancreas cancer immunotherapy will be presented during a poster session at the American Society of Clinical Oncology 2011 Gastrointestinal Cancers Symposium in San Francisco, California. A summary of the poster is below. Title: Effect of the addition of algenpantucel-L immunotherapy to standard adjuvant...
LONDON, January 6, 2011 /PRNewswire/ -- - Agreement Focuses on Innovative Cellular Treatments for EBV Associated Cancers - Positive Results Already Seen in Current Clinical Development - Significant Market Potential, Estimated to Exceed $1.0 billion Cell Medica, a leading cellular therapeutics company which develops, manufactures and markets cellular immunotherapy products for the treatment of infectious disease and cancer, is pleased to announce an exclusive...
The promise of vaccines targeted against various types of cancer has raised the hopes of patients and their families. The reality, however, is that these promising treatments are difficult to develop. One of the challenges is identifying a discrete cellular target to stop cancer growth without inactivating the immune system. Scientists at UNC Lineberger Comprehensive Cancer Center report a laboratory finding that has the potential to increase the effectiveness of therapeutic cancer...
